Basic fibroblast growth factor (FGF) is a multifunctional peptide that may play an integral role
in angiogenesis associated with coronary collateral formation and myocardial infarct healing…

BACKGROUND Vascular endothelial growth factor (VEGF) is an endothelial cell-specific
mitogen that is angiogenic in vitro and in vivo. It has been hypothesized that VEGF plays a role …

We sought to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of basic
fibroblast growth factor (bFGF), administered as a single intracoronary injection, to subjects …

Background We have shown that the angiogenic peptides basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF) enhance canine coronary collateral …

Serious and fatal bleeding events associated with use of the anticoagulant dabigatran have
been reported. The FDA used the Mini-Sentinel database to determine that the actual rates …

Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
| NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube …

Randomized trials have endeavored to show that using ESAs to raise hemoglobin concentrations
to higher targets improves clinical outcomes in patients with anemia associated with …

Background : Concerns exist that women are underrepresented in trials of cardiovascular
medications. Objectives : The authors sought to examine women’s participation and the …

Background Recently we reported that intracoronary administration of basic fibroblast
growth factor (bFGF), a potent angiogenic peptide, increases collateral blood flow in dogs …

Objective: We have shown that basic fibroblast growth factor (bFGF/FGF-2) enhances
myocardial collateral development in a canine model of progressive coronary occlusion when …